
New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.
The AstraZeneca–BMS merger story explained: what was reported, what was denied, what regulators would scrutinize, and what it means for pharma.
Last week, reports emerged of a potential merger between





